Page last updated: 2024-12-09
5-chloro-2-mercaptobenzothiazole
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 2723842 |
| CHEMBL ID | 1456330 |
| SCHEMBL ID | 347929 |
| SCHEMBL ID | 9497675 |
| MeSH ID | M0534450 |
Synonyms (74)
| Synonym |
|---|
| AC-4806 |
| sh-benzothiazole |
| nsc3934 |
| nsc-3934 |
| 2(3h)-benzothiazolethione, 5-chloro- |
| 5-chloro-2-benzothiazolethiol |
| wln: t56 bn dsj csh hg |
| 2-benzothiazolethiol, 5-chloro- |
| benzothiazole, 5-chloro-2-mercapto- |
| 5331-91-9 |
| 5-chloro-2-mercaptobenzothiazole , |
| smr000129383 |
| MLS000518963 , |
| 5-chloro-1,3-benzothiazole-2-thiol |
| 5-chloro-2-mercaptobenzothiazole, zinc salt |
| 53404-93-6 |
| einecs 226-235-0 |
| nsc 3934 |
| EU-0002999 |
| 5-chloro-2-mercaptobenzothiazole, technical grade, >=90% |
| MAYBRIDGE1_006216 |
| STK396220 |
| HMS559C12 |
| inchi=1/c7h4clns2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3h,(h,9,10) |
| nkydkcvznmnzcm-uhfffaoysa- |
| 5-chloro-3h-1,3-benzothiazole-2-thione |
| AKOS001260730 |
| AKOS000120378 |
| NCGC00245945-01 |
| HMS2502H14 |
| 2-metcapto-5-chloro-benzothiazole |
| A829509 |
| 5-chlorobenzothiazole-2-thiol |
| unii-r9099u429r |
| r9099u429r , |
| REGID_FOR_CID_2723842 |
| AB00531 |
| 5-chlorobenzo[d]thiazole-2(3h)-thione |
| FT-0620259 |
| SCHEMBL347929 |
| AB00128201-12 |
| SCHEMBL9497675 |
| 5-chlorobenzo[d]thiazole-2-thiol |
| cmbt |
| 5-chloro-benzothiazole-2-thiol |
| 5-chloro-benzothiazol-2-thiol |
| W-105752 |
| J-640164 |
| 5-chloro-3h-benzothiazole-2-thione |
| 5-chloro-1,3-benzothiazol-2-yl hydrosulfide |
| bdbm59826 |
| cid_2723842 |
| 5-chloranyl-3h-1,3-benzothiazole-2-thione |
| CHEMBL1456330 |
| 5-chloro-2(3h)-benzothiazolethione |
| 5-chlorobenzothiazoline-2-thione |
| 2-mercapto-5-chlorobenzothiazole |
| mfcd00005783 |
| 5-chloro-1,3-benzothiazole-2(3h)-thione |
| DTXSID0022224 |
| 5-chloro-2,3-dihydro-1,3-benzothiazole-2-thione |
| AS-63163 |
| SR-01000414406-1 |
| sr-01000414406 |
| NCGC00245945-02 |
| F15179 |
| F0771-0819 |
| 5-chloro-2-mercaptobenzothiazine |
| EN300-21446 |
| Q27287987 |
| CS-W015535 |
| 5-choro-2-mercapto benzothiazole |
| SY048666 |
| Z104497390 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (22)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 8.9125 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 25.1189 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 35.4813 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 6.7016 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 2.8184 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 5.0119 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| IDH1 | Homo sapiens (human) | Potency | 22.3872 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 1.7783 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 27.9687 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 28.1838 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 1.8888 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 22.1061 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| Vpr | Human immunodeficiency virus 1 | Potency | 25.1189 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.0580 | 10.6949 | 26.6086 | AID602310 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 25.1189 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 14.1254 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 25.1189 | 0.0063 | 8.2350 | 39.8107 | AID881 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 0.8913 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 35.4813 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Proteasome subunit beta type-8 | Homo sapiens (human) | IC50 (µMol) | 32.0000 | 0.0013 | 0.3698 | 5.0000 | AID1763210 |
| M17 leucyl aminopeptidase | Plasmodium falciparum 3D7 | IC50 (µMol) | 14.7800 | 1.0000 | 27.8360 | 138.0800 | AID1619 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| MSRA protein | Bos taurus (cattle) | EC50 (µMol) | 103.9190 | 3.6370 | 4.0500 | 4.4630 | AID623963 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (123)
Molecular Functions (42)
Ceullar Components (37)
Bioassays (14)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1763210 | Inhibition of human chymotrypsin-like beta 5i subunit of iCP using suc-LLVY-AMC as flurogenic substrate for 90 mins by fluorescence-based assay | 2021 | European journal of medicinal chemistry, Jul-05, Volume: 219 | Discovery of selective fragment-sized immunoproteasome inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.91
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.91) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||